Forty Seven fortyseveninc.com


Public list: Smart Money VCs (6327) Pharma Startups (4733) Cancer Therapeutics (1133) Google In Healthcare (60)

Forty Seven is a clinical-stage immuno-oncology company that is developing therapies licensed from Stanford University targeting cancer immune evasion pathways. The lead program Hu5F9-G4 is a monoclonal antibody against the CD47 receptor, a "don't eat me" signal that cancer cells commandeer to avoid being ingested by the immune system. This antibody is currently being evaluated in two Phase 1 clinical studies in patients with solid tumors and in patients with acute myeloid leukemia.

Forty Seven is a clinical-stage immuno-oncology company that is developing therapies licensed from Stanford University targeting cancer immune evasion pathways. The lead program Hu5F9-G4 is a monoclonal antibody against the CD47 receptor, a "don't ea...Show all

Company (Alive / Active)

Phone: 650-352-4150

Fax:

1490 O'Brien Drive
Suite A
Menlo Park, 94025
California, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Forty Seven $155M Dec 6, 2017
See all 12 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Forty Seven Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 7 investors

Competitors

Company Status Description Investors

BeneVir Biopharm

Rockville, Maryland, United States
AcquiredBeneVir is a privately held biopharmaceutical company founded in 2011 with offices and laboratories located in Rockville, MD. BeneVir is developing a novel platform of cancer immuno-therapies based on oncolytic viruses to help patients with hard-to-treat cancers. In 2012, BeneVir received two Small Business Innovation Research (SBIR) grants from the National Cancer Institute, which supported proof-of-concept studies. BeneVir's immunotherapies for cancer are designed to induce the immune system t...Show allLogin to see details

Neon Therapeutics

Cambridge, Massachusetts, United States
Alive / ActiveNeon Therapeutics is an immuno-oncology company focused on developing novel therapeutics leveraging neoantigen biology to treat cancer. A neoantigen-based product engine allows Neon to develop multiple treatment modalities, including next-generation vaccines and T cell therapies targeting both personalized and shared neoantigens. Neon's lead program is a personalized neoantigen vaccine that builds upon years of research and development at the Broad Institute and Dana-Farber Cancer Institute, and...Show allLogin to see details
See all 12 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Disrupting fc receptor engagement on macrophages enhances efficacy of anti-sirpalpha antibody therapy Jul 26, 2017 Application